Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, open-labeled, randomized phase III clinical trial
comparing overall response rate (ORR), progression free survival (PFS), overall survival (OS)
and toxicity obtained with gemcitabine cisplatin combination (GP) versus gemcitabine
paclitaxel combination (GT).
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Collaborators:
307 Hospital of PLA Changhai Hospital Sun Yat-sen University The Affiliated Hospital of the Chinese Academy of Military Medical Sciences Tianjin Medical University Cancer Institute and Hospital Zhejiang Cancer Hospital